Dyne Therapeutics elects Vikram Karnani as Class II director effective Dec 22, 2025

Dyne Therapeutics, Inc.

Vikram Karnani elected to the Board as an independent director; term expires at 2028 Annual Meeting.
Received option to purchase 59,665 shares at $20.78/share, vesting monthly over three years.
Will receive annual cash compensation of $45,000 plus standard equity grants under non-employee director plan.
No family relationships or material transactions with the Company; standard indemnification agreement entered.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.